Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesPrognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Annals of Oncology, 10/19/09
Syrigos KN et al. – NSCLC histology significantly predicts efficacy outcomes for patients receiving pemetrexed. Several other factors are prognostic for the overall study population as well as a subset of patients with advanced nonsquamous NSCLC.
Methods- Randomized phase III study in 1725 chemonaive patients with stage IIIB or IV NSCLC and Eastern Cooperative Oncology Group performance status (PS) of 0
- Histology confirmed to be predictive of CP efficacy and may also be prognostic
- Gender, ethnicity, disease stage, smoking status, and PS not predictive in either treatment arm but were shown to be prognostic in the nonsquamous population, consistent with the results in overall NSCLC population
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
An Umbrella Review: Corticosteroid Therapy for Adults with Acute Asthma
American Journal of Medicine, 10/27/09
Magnesium sulphate in the treatment of acute asthma: evaluation of current practice in adult emergency departments
Emergency Medicine Journal, 10/27/09
Intravenous Sildenafil in the Treatment of Neonates with Persistent Pulmonary Hypertension
The Journal of Pediatrics, 10/19/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase III study
The Lancet, 10/26/09
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09
Weekly paclitaxel and cisplatin in the treatment of elderly advanced non-small cell lung cancer
Chinese Journal of Lung Cancer, 10/26/09
Sponsor
Article Search
Sponsor